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Paul J. Martin,1,2 Yoshihiro Inamoto,1,2 Mary E. D. Flowers,1,2 Paul A. Carpenter1,3Management of steroid-resistant or steroid-refractory acute graft-versus-host disease (aGVHD) poses one
of the most vexing and difficult problems faced by transplantation physicians. In the current study, we used 10
criteria to evaluate 67 reports describing secondary treatment of patients with aGVHD. The goal of this ex-
ercise was not only to provide a critical summary of the literature but also to offer suggestions that could
improve future studies. Areas especially in need of improvement include the use of a consistent treatment
regimen, the assessment of response at a consistent prespecified time point, consideration of concomitant
treatment in assessing response, documentation that selection bias was minimized, and the use of methods
that test a formal statistical hypothesis based on a contemporaneous or historical benchmark. Our results
suggest that previous published reports collectively offer little guidance in discerning the most effective treat-
ments for patients with steroid-resistant or steroid-refractory aGVHD. Adherence to the proposed criteria
in future reports would enable meaningful comparisons across studies and thereby accelerate progress in
evaluating new treatments for patients with aGVHD.
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Allogeneic hematopoietic cell transplantation is
frequently complicated by acute and chronic graft-
versus-host disease (aGVHD and cGVHD) [1,2].
Management of steroid-resistant or steroid-refractory
aGVHD poses one of the most vexing and difficult
problems faced by transplantation physicians. Many
retrospective reviews and prospective studies have
been carried out to evaluate approaches for secondary
treatment of patients with aGVHD. To date, no con-
sensus has been reached regarding the optimal choice
of agents for secondary treatment, and clinicalmanage-
ment is generally approached through empirical trial
and error. Treatment choices are based on physician
experience, ease of use, need for monitoring, risk of
toxicity, and potential exacerbation of pre-existing
comorbidity [3].
In a previous review, we used a list of 10 criteria to
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6/j.bbmt.2012.04.006cGVHD [4]. Less than 10%of the reports documented
an effort to minimize patient selection bias, used a con-
sistent treatment regimen, or tested a formal statistical
hypothesis that was based on a contemporaneous or
historical benchmark. Only 22% of the reports had
a prespecified time for assessment of response, and
only 35% to 45% of the reports provided adequate in-
formation regarding eligibility criteria, concomitant
treatment, and overall survival. Based on these obser-
vations, we concluded that previous studies offer little
guidance in discerning the most effective treatments
for patients with steroid-resistant or steroid-refractory
cGVHD. In the current study, we used the same list
of 10 criteria to evaluate reports describing secondary
systemic treatment of patients with aGVHD.METHODS
Literature Search
We searched the Medline (PubMed) database us-
ing a broad search strategy to identify studies evaluat-
ing secondary treatment of aGVHD with reports
published between 1990 and 2011. The search was
conducted using the terms ‘‘Graft versus host disease’’
and ‘‘Treatment’’ excluding ‘‘Review.’’ Relevant refer-
ences in the publications identified were also reviewed.
Both retrospective and prospective studies were in-
cluded, but studies with cohorts containing fewer
than 10 patients, case reports, and studies of agents
that are not commercially available were excluded.
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Each report was evaluated according to the follow-
ing 10 criteria.
1. Adequately defined eligibility criteria. Inclusion
and exclusion criteria should specify affected sites,
severity of manifestations, and prior treatment
used to define the cohort. Exclusion criteria should
indicate whether factors such as the presence of
infection, inability to tolerate the study treatment,
presence of persistent malignancy, or low perfor-
mance scorewere used to define the cohort. Studies
intended to evaluate treatment of ‘‘steroid-refrac-
tory’’ GVHD should indicate the glucocorticoid
dose and duration of treatment used to define the
cohort. Eligibility criteria are typically more pre-
cisely defined for prospective studies than for retro-
spective studies. Data from retrospective studies
describing all patients who received the study treat-
ment of interest are difficult to interpret unless
additional selection criteria are applied to improve
homogeneity within the study cohort.
2. Documented minimization of bias in the selec-
tion of patients. Readers should be given enough
information to determine whether the characteris-
tics of the patients included in a study are represen-
tative of the more general population of patients
with steroid-resistant or steroid-refractory
aGVHD. Risk factors that could affect outcomes
should be delineated. Ideally, either a historical
or contemporaneous cohort should be identified
for comparison, and any differences in the preva-
lence of risk factors between the study cohort and
the comparison cohort should be noted. The use
of randomization to define cohorts helps to ensure
the absence of bias, but this procedure does not en-
sure that the study cohort is representative of the
more general population of patients with the indi-
cation of interest. Enrollment of all consecutive
patients whomeet eligibility criteria could provide
a representative cohort but would raise ethical
questions about informed consent.
3. Consistent treatment regimen.The study treat-
ment of interest should be administered in a consis-
tent manner in dose, schedule, and duration of
administration. Differences in dose, schedule, or
duration of administration can be addressed by
stratified analysis of each specific subgroup. As
much as possible, concomitant treatment with
immunosuppressive agents other than glucocorti-
coids should also be administered in a consistent
manner in order to facilitate the interpretation of
results. Such consistency greatly improves the abil-
ity to interpret results and to confirm the results in
subsequent studies. Concomitant treatment can
be standardized more easily in studies of initialtherapy for standard or high-risk disease and for
secondary therapy than for subsequent therapies.
For third-line or subsequent therapy, such consis-
tency is feasible only if prior treatment with agents
other than glucocorticoids is discontinued.
4. Objective criteria for organ response.Categor-
ical criteria should be defined for complete
response, partial response, stable disease, and
worsening for each organ or site affected by
GVHD, because conclusions of the study are
based on response rates. Definitions require for-
mal assessment at baseline and at the comparison
time point. Scales for staging organ severity and
overall GVHD grade can be used for this purpose.
5. Unambiguous criteria for overall response.
The definition of overall response is distinct
from the criteria for organ response. Overall re-
sponses are often defined according to the overall
pattern of organ responses. At a minimum, overall
partial response indicates improvement in at least
one organ. The category assigned for patients with
improvement in one organ but deterioration in an-
other organ should be clearly stated.
6. Prespecified time for assessment of response.
To facilitate comparisons between studies, at least
one specified time point should be used for assess-
ment of response, and the data for this assessment
should be shown. Additional information can be
shown as a time-to-initial partial or complete re-
sponse or as time-to-initial complete response,
but this approach cannot account for subsequent
loss of response. The number of patients who
died, had recurrentmalignancy, or had a treatment
change before the assessment time point should
be specified, and the results should clearly indicate
whether these patients were excluded from consid-
eration in the assessment of response or whether
they were included as nonresponders. Tabulation
of results according to ‘‘best response’’ or ‘‘last
value carried forward’’ is not appropriate because
these categories do not reflect clinical benefit at
a specific time point.
7. Concomitant treatment taken into account.
New systemic treatment for patients with GVHD
added after enrollment but before the assessment
time point because of inadequately controlled dis-
ease manifestations should be categorized as non-
response. Even in studies that use ‘‘best response’’
as the endpoint, the text should state whether re-
sponse was evaluated before any new systemic
treatment was added. Changes in glucocorticoid
dose should be described, but a temporary small in-
crease in glucocorticoid dose during a taper should
not be categorized as nonresponse, because tempo-
rary flares of GVHD activity cannot be avoided
when conscientious efforts are made to determine
Table 1. Initial Agreement between Evaluatorsa
Criterion Percent Agreement
Eligibility criteria 60
Minimization of selection bias 81
Consistent treatment regimen 61
Organ response criteria 82
Overall response criteria 75
Prespecified time of assessment 84
Concomitant treatment 60
Historical benchmark 93
Statistical hypothesis 97
Survival curve 76
aEach of the 67 selected reports was independently evaluated by 2 re-
viewers. Results in the table indicate the percent initial agreement be-
tween the 2 reviewers for each criterion.
Figure 1. Treatments evaluated in prior reports. Treatments are listed
in order of frequency among the 67 reports included in the literature
review.
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control GVHD.
8. Well-established control benchmark. A specific
historical or concurrent control benchmark
should be used to establish a null hypothesis for
the primary endpoint. Response criteria for the
benchmark and study cohorts should be identical
or closely similar.
9. Statistical hypothesis and power estimate. The
methods should provide values for the null and al-
ternative hypotheses and for the 1-sided or 2-sided
type 1 error, together with estimates of statistical
power and the necessary sample size. Although
these considerations might be difficult to apply
in retrospective studies, they should always be ap-
plied in prospective studies.
10. Survival. The results should show survival of the
cohort from the onset of study treatment.
Kaplan-Meier curves should show tic marks de-
picting end of follow-up, especially if the mini-
mum follow-up time for surviving patients is less
than 6 months. Alternatively, results can be shown
in tables indicating time to death or last follow-up
for each patient.When response definitions differ,
these data provide the only gauge that can be used
as a simple and universally applicable method for
comparisons with other studies.Review Procedures
Two individuals (PAC and PJM) independently
reviewed reports of studies testing the use of agents
for secondary treatment of patients with aGVHD.
Reports were evaluated according to whether each
criterion was met or not, based on careful reading of
the text. Differences in assessments were reconciled
by joint review to arrive at a consensus.RESULTS
A total of 67 studies were selected for review [5-71].
Initial agreement between the 2 reviewers in assessing
the 10 criteria ranged between 60% and 97%(Table 1). Agreement was less than 80% for 5 of the
10 criteria, including adequately defined eligibility cri-
teria, use of a consistent treatment regimen, unambig-
uous criteria for overall response, accounting for
concomitant treatment in the assessment of response,
and survival data. Judgments sometimes differed with
respect to the level of detail needed for adequate char-
acterization of the inclusion and exclusion criteria, the
importance of using the agent of interest at exactly the
same dose in all patients, and the feasibility of harmo-
nizing concomitant immunosuppressive treatment in
all patients. The reviewers agreed that allowances can
be made for minor differences in dose of the agent un-
der investigation and that concomitant treatment can
be harmonized with respect to agents previously used
for treatment but not for agents previously used for
prophylaxis. Some differences of opinion were caused
by ambiguities in the definitions of response in patients
whohad improvement in one organwith progression in
another organ andby an absence of explicit information
explaining how response was evaluated in patients who
had additional agents added before the response was
evaluated. Differences regarding survival information
were mostly related to confusion about follow-up
time for surviving patients. The criterion requires in-
formation about follow-up time only when the mini-
mum follow-up time is less than 6 months.
Across the 67 studies, 19 different agents were
evaluated (Figure 1). Horse antithymocyte globulin
and extracorporeal photopheresis were the most fre-
quently studied agents (n 5 8 and 7, respectively) fol-
lowed by mycophenolate mofetil, inolimomab,
daclizumab (n 5 6 each), combinations of agents
(n 5 5), sirolimus, infliximab, and alemtuzumab
(n 5 4 each), and methotrexate and basiliximab
(n 5 3 each). The distribution of scores representing
the total number of criteria met by each report ranged
from a low of 0 (n 5 1) up to a maximum of 8 (n 5 1;
Figure 2). The mean score for all 67 reports was 4.2
and did not differ between retrospective studies
Figure 2. Distributionof scores representing the total numberof criteria
met by each report for the 67 studies included in the literature review.
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between single-center studies (n5 46) compared with
multicenter studies (n 5 21; Table 2). Reports pub-
lished before 2000 (n 5 7) had a mean score of 3.4,
compared with 4.3 for those reported since then
(n 5 60; Table 3). The proportion of reports with
adequately defined eligibility criteria and survival
information improved across time.
In 57% to 88% of all reports, adequate informa-
tion regarding eligibility criteria, organ response crite-
ria, overall response criteria, and overall survival was
provided (Table 2). Only one-third of all reports de-
scribed a consistent treatment regimen, assessed re-
sponse at a prespecified time point, and accounted
for effects of concomitant treatment. As might have
been expected, treatment regimens were more fre-
quently administered consistently in prospective stud-
ies (61%) than in retrospective studies (27%). Only
18% of the reports demonstrated an effort to minimize
or account for bias in the selection of patients. Reports
of two phase 2 studies described a formal statistical hy-
pothesis. In these 2 reports, the benchmark overall
response rates for the null hypothesis were set at
20% [13] and 50% [38], respectively, without refer-
ence to prior experience or results of other studies.
Six reports described prior local [18,30,44,58] orTable 2. Assessment of Prior Reports, According to Study Typea
Criterion
Perc
Total (n 5 67) Retrospectiveb (n 5 44)
Eligibility criteria 57 55
Minimization of selection bias 18 20
Consistent treatment regimen 39 27
Organ response criteria 88 89
Overall response criteria 73 77
Prespecified time of assessment 34 32
Concomitant treatment 37 43
Historical benchmark 10 9
Statistical hypothesis 4 0
Survival curve 61 64
Average total score 4.2 4.2
aData in the table indicate the percentage of reports in each category that we
bIn 3 reports, the retrospective or prospective design of the study was not clexternal experience [19], or randomized controls [48]
for the evaluation of results, but without testing formal
null and alternative statistical hypotheses. One report
described a formal statistical hypothesis with random-
ized controls [52].
DISCUSSION
The number of deficiencies in reports was some-
what lower for studies of secondary treatment of
aGVHD compared with studies of secondary treat-
ment of cGVHD [4]. The average score for all 67 re-
ports was 4.3 for aGVHD studies, compared with
2.5 for all 60 reports of cGVHD studies during the
same time period [4]. Compared to cGVHD studies,
aGVHD studies seemed to have fewer deficiencies in
the use of well-defined eligibility criteria, a consistent
treatment regimen, objective response criteria and un-
ambiguous overall response criteria, and in reporting
survival data. Reports of aGVHD treatment seemed
to focus more frequently on second-line treatment,
with less frequent aggregation of results for second-
line treatment with those for third, fourth, and subse-
quent lines of treatment. These eligibility criteria
could have made it more feasible to apply a consistent
treatment regimen in aGVHD studies as compared
with cGVHD studies. The availability of long-
established and widely accepted scales for assessment
of organ stages and overall grade has facilitated the
use of objective response criteria in studies of aGVHD
[72-74]. The development of similar scales for
cGVHD has been hampered by the multiple protean
manifestations of this disease and its greater
complexity as compared to aGVHD [75].
Many deficiencies remain in reports of aGVHD
studies. Areas especially in need of improvement in-
clude the use of a consistent treatment regimen, the as-
sessment of response at a consistent prespecified time
point, consideration of concomitant treatment in as-
sessing response, documentation that selection bias
was minimized, and the use of methods that testent of Reports Fulfilling Criterion
Prospective (n 5 23) Single Center (n 5 46) Multicenter (n 5 21)
61 54 62
13 17 19
61 39 38
87 87 90
65 67 86
39 35 33
26 39 33
13 7 19
13 2 10
57 67 48
4.4 4.2 4.4
re judged to meet each of the indicated criteria.
early stated.
Table 3. Assessment of Prior Reports According to Year of
Publicationa
Criterion
Percent of Reports
Fulfilling Criterion
1990-1999
(n 5 7)
2000-2004
(n 5 19)
2005-2011
(n 5 41)
Eligibility criteria 29 53 63
Minimization of selection bias 0 16 22
Consistent treatment regimen 57 32 39
Organ response criteria 100 74 93
Overall response criteria 71 84 68
Prespecified time of assessment 29 53 27
Concomitant treatment 29 42 37
Historical benchmark 0 11 12
Statistical hypothesis 0 5 5
Survival curve 29 58 68
Average total score 3.4 4.3 4.3
aData in the table indicate the percentage of reports in each category
that were judged to meet each of the indicated criteria.
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neous or historical benchmark. To facilitate the devel-
opment of new treatment for aGVHD, the American
Society of Blood and Marrow Transplantation has en-
dorsed recommendations that could improve the con-
duct and reporting of future studies [76].
Prior GVHD therapies should be discontinued in
studies that include patients with third, fourth, and
subsequent lines of treatment in order to establish
a consistent treatment regimen, so that valid compari-
sons can be made with results of other studies. For
studies of initial treatment for aGVHD, a consensus
may be emerging that response should be evaluated
at day 28, and strong agreement has emerged that pa-
tients who are given additional therapy before the as-
sessment day should be classified as not having
a response. Although the day-28 response assessment
might not necessarily serve as the best measure of suc-
cess in studies of secondary therapy, comparisons be-
tween studies would be facilitated if these results
were routinely reported. In addition, a survival plot
should be included routinely in order to facilitate com-
parisons between studies.
The involvement of only 2 reviewers and the in-
complete agreement between reviewers in judging
whether reports met criteria are limitations of the cur-
rent study. We considered the merits of recruiting
a larger number of reviewers to assess and grade the
published reports, but we decided that this extra effort
would be unlikely to change the conclusion that the
published reports have many deficiencies. To some ex-
tent, ambiguity in the initial description of the criteria
contributed to lack of agreement between the re-
viewers. The reviews were done in 3 stages, and at
the end of each stage, the definitions were refined in
an effort to eliminate ambiguities and to clarify the cri-
teria. In many cases, discrepant assessments between
the reviewers were related to the interpretation of am-
biguous language in the report. Because the purpose ofpublication is to persuade others, application of the
criteria was very strict, and no credit was given if the
text did not address the criterion or if the text was
not clear. Therefore, in many cases, deficiencies in
the report might not have been representative of
a study as it was actually conducted. Important details
could have been omitted from some reports because of
word limits. When necessary, future reports could
provide this information in online supplements. The
proposed criteria do not directly measure the diligence
of the investigator in ensuring that the data are accu-
rate and unbiased. Such an assessment would require
onsite monitoring to compare the data against source
documents.
Although the 2 reviewers did not have perfect
agreement regarding each criterion in each study, it
was clear that the reports had many deficiencies. Our
results suggest that previously published reports col-
lectively offer little guidance in discerning the most ef-
fective treatments for patients with steroid-resistant
or steroid-refractory aGVHD. Adherence to the pro-
posed criteria in future reports would enable meaning-
ful comparisons across studies and thereby accelerate
progress in evaluating new treatments for patients
with aGVHD. Promising candidate treatments identi-
fied in robust phase II studies could be taken forward in
phase III studies of secondary treatment, and success-
ful results in such a study would establish a new bench-
mark for future phase II studies of secondary therapy.
Promising candidate treatments could also be tested in
phase II studies of primary treatment. Most impor-
tantly, successful results in phase III studies of either
secondary or primary treatment would improve pa-
tient outcomes and establish new standards of care.ACKNOWLEDGMENTS
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